Delcath Systems Third Quarter 2026 Earnings Call - DELCATH SYSTEMS INC

Financial Performance:

• Third quarter 2026 total revenue reached $35.1 million, a 71% year-over-year increase from $20.6 million in Q3 2025.
• HepsadoKit revenue was $32.7 million (up 72% YoY), while Chemostat revenue was $2.4 million (up 85% YoY).
• Gross margin improved to 89% in Q3 2026 compared to 87% in the prior year period.
• Net income totaled $7 million, a significant increase from $0.8 million in Q3 2025.
• Non-GAAP adjusted EBITDA was $11.5 million, up from $5.3 million in the prior year quarter.
• Operating cash flow was positive at $8.2 million for the quarter.
• The company ended the quarter with $104.3 billion in cash investments and zero debt.
• R&D expenses increased to $11 million, and SG&A expenses rose to $13.1 million due to commercial expansion and clinical headcount.

Guidance and Future Outlook:

• Full-year 2026 total revenue guidance was raised to $115–$117 million.
• Q4 2026 revenue is projected to be $25.8–$27.8 million, reflecting a 25–34% year-over-year growth rate.
• Management anticipates at least 41% HepsadoKit volume growth for the full year 2026 compared to 2025.
• Full-year gross margin is expected to remain between 87% and 89%.
• The company expects to report positive adjusted EBITDA for the full year 2026.
• Q4 revenue is lower than Q3 primarily due to the loss of approximately two weeks of treatment time during the holiday season and historically slower new patient starts.

Business Segments and Product Lines:

• The HepsadoKit platform continues to drive growth, with over 1,000 commercial treatments administered in the U.S. this quarter.
• The treatment network expanded to 33 active centers in the U.S., with new activations including University of Nebraska and AdventHealth.
• Management targets at least 36 active centers by year-end, with two additional centers scheduled to begin treatment in the coming weeks.
• Average new patient starts accelerated to approximately 0.6 per site per month in Q3 2026.
• Combination therapy with systemic treatments is becoming the standard of care, with many physicians viewing the approaches as complementary.
• Clinical pipeline includes a Phase 2 colorectal trial targeting an interim analysis in mid-2027.
• A breast cancer trial enrollment is slower than anticipated; however, the first patient was dosed in July at the European Institute of Oncology.
• Planned IND submission for cholangiocarcinoma in early 2027.
• Preclinical development is underway for an oxaliplatin-based PHB program targeting liver-dominant cancers, with a potential IND by mid-2027 pending FDA agreement.

Market and Competitive Landscape:

• Adoption of the therapy is broadening, driven by word-of-mouth, patient demand, and demonstrated efficacy at major academic centers.
• Large integrated health systems like AdventHealth are facilitating system-wide referrals, leveraging their networks of primary care and oncology practices.
• Oxford (referred to as "Chopin" in transcript context) has provided a foundation for treatment sequencing, moving the therapy into combination regimens rather than sole reliance.
• The oxaliplatin-based program aims to address toxicity concerns associated with melphalan, potentially allowing first or second-line use in colorectal liver metastases.
• The 340B rule changes are viewed by management as net neutral to net positive regarding ASPs without impacting volume.

Risks and Challenges:

• Breast cancer trial enrollment has been slower than initially projected, creating uncertainty regarding interim analysis timing.
• Future guidance assumes a step-down in Q4 due to holiday closures and seasonal trends in new patient starts.
• New center activations carry a risk of cancellation; management noted variability in past projections and offered no guarantees on the final year-end center count.
• Clinical trial execution remains a key execution risk, particularly regarding site activation and patient recruitment timelines.
• R&D spending is expected to remain elevated in 2027 to support the growing pipeline and increased clinical trial activity.

Management Commentary and Tone:

• Management expressed strong confidence, citing "record" third-quarter results and successful operating leverage.
• CEO Gerard Michel attributed outperformance to four key factors: normalization of combination therapy, patient demand, resolution of clinical trial headwinds from the previous year, and improved operational capacity (backup teams for perfusionists and anesthesiologists).
• CFO Sandra Pinnell highlighted the structural improvement in profitability and the transition to a fully staffed commercial team across nine regions.
• The tone was optimistic regarding the commercial trajectory while maintaining caution on clinical trial timelines.

Analyst Questions and Answers:

• Drivers of Q3 Outperformance: Management cited increased combination therapy usage extending treatment duration, patient advocacy, reduced clinical trial headwinds, and operational improvements in scheduling capacity.
• Expense Outlook: R&D spending is expected to rise quarter-over-quarter into 2027 due to pipeline expansion, while SG&A is expected to remain relatively flat as the sales team is nearly fully staffed.
• Q4 Guidance Logic: The implied revenue step-down in Q4 is attributed to two weeks of holiday closures and historically lower new patient starts (0.3–0.35 vs. 0.6 in Q3), rather than a change in underlying growth trends.
• Pipeline Updates: Colorectal cancer interim analysis is expected in Q2 or Q3 of 2027; breast cancer trial enrollment remains active but slow.
• Center Network: While 36 centers is the current target, management noted potential for variability based on the status of six additional sites in various stages of activation.
• 340B Impact: Management anticipates the new 340B rules will have a neutral or slightly positive effect on average selling prices.

Other Key Points:

• The transcript contains a discrepancy where "Hepzato" and "Chopin" are used interchangeably with "HepsadoKit," likely referring to the same proprietary hepatic perfusion technology.
• A specific milestone was reached with the 500th Chemostat procedure performed at University Hospital Southampton.
• The company emphasized the strategic value of the oxaliplatin-based PHB product, leveraging physician familiarity with the agent to reduce toxicity risks compared to melphalan.
• Forward-looking statements were standardly disclaimed, referencing risks detailed in SEC filings.